MNK Proteins as Therapeutic Targets in Leukemia

Candice Mazewski*, Leonidas C. Platanias*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


In leukemia, resistance to therapy is a major concern for survival. MAPK-interacting kinases (MNKs) have been identified as important activators of oncogenic-related signaling and may be mediators of resistance. Recent studies in leukemia models, especially acute myeloid leukemia (AML), have focused on targeting MNKs together with other inhibitors or treating chemotherapy-resistant cells with MNK inhibitors. The preclinical demonstrations of the efficacy of MNK inhibitors in these combination formats would suggest a promising potential for use in clinical trials. Optimizing MNK inhibitors and testing in leukemia models is actively being pursued and may have important implications for the future. These studies are furthering the understanding of the mechanisms of MNKs in cancer which could translate to clinical studies.

Original languageEnglish (US)
Pages (from-to)283-295
Number of pages13
JournalOncoTargets and Therapy
StatePublished - 2023


  • AML
  • MAPK
  • MNK
  • eIF4E
  • resistance

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'MNK Proteins as Therapeutic Targets in Leukemia'. Together they form a unique fingerprint.

Cite this